SLINTEC signs a landmark agreement with J L Morison Son & Jones
From Left: Mr. Priya Dissanayake (J.L. Morison’s Group), Mr. Trihan Perera (Managing Director, J.L. Morison’s Group), Steven Enderby (CEO, Hemas Holdings PLC), Dr. Nihal Vitharana (Director, SLINTEC), Mr. Anushman Rajaratnam (Director, SLINTEC), Prof. Gehan Amarathunga (SLINTEC), Mr. Sunanda Gunasekera (SLINTEC) and Mr. Revan Weerasinghe (SLINTEC)
SLINTEC is pleased to announce the signing of a landmark agreement with pharmaceutical giant J L Morisons to become the first anchor tenant to the Nanotechnology and Science Park. It is the first large scale pharmaceutical company to sign with SLINTEC with the aim of developing their manufacturing processes with close access to SLINTEC’s premier science and engineering services including access to the high end equipment base. As part of the agreement J L Morisons will also have a significant research commitment with SLINTEC with a view to improving the functions of the existing product range and also initiate new product development.
SLINTEC is a public-private partnership between the Government of Sri Lanka and major players in the private sector; namely MAS Holdings, Brandix, Dialog, Hayleys, Loadstar and most recently Lankem. SLINTEC is committed to support the small-and-medium enterprises to improve and develop their products to meet the demands of the local and international markets using nanotechnology and advanced technology solutions.
J L Morison Son & Jones is a Sri Lanka Pharmaceutical subsidiary of Hemas Holdings PLC with seven decades of experience and working relationships in Sri Lanka. J L Morison’s are importers and distributors of internationally renowned products as well as manufacturers of high quality general pharmaceuticals.
